Logo

Professor Thierry Facon presents MAIA-study

A phase 3 randomised study of daratumumab plus lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant.


CP-130012


DARZALEX® (DARATUMUMAB) short SPC, click here

CP-130489